Search - tctmd.com

Displaying 161 - 180 of 250

Sort: Relevancy | Date

Presentation TCT 2016

Importance of Unmeasured Confounders in Observational Registries: ASCERT and Other Examples

Presenter: Eugene H. Blackstone, Robert W. Yeh, Kirk N. Garratt

October 30, 2016

Presentation TCT 2016

Value and Hazards of Subgroup Analysis: the SYNTAX to EXCEL Case Study

Presenter: Peter Juni, E. Magnus Ohman, Ori Ben-Yehuda

October 30, 2016

Presentation TCT 2016

Clinical Trial Interpretation: Relative vs Absolute Differences

Presenter: Peter Juni, E. Magnus Ohman, John A. Bittl

October 30, 2016

Presentation TCT 2016

Levels of Evidence: Single-center vs Multicenter Trials

Presenter: Peter Juni, E. Magnus Ohman, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Should Clinical Trial Interpretation Be Dominated by A P Value of 0.05 for the Primary Endpoint?

Presenter: Peter Juni, E. Magnus Ohman, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Presenter: Roxana Mehran, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Presenter: Roxana Mehran, Pascal Vranckx, John A. Spertus

October 30, 2016

Presentation TCT 2016

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Presenter: Roxana Mehran, Pascal Vranckx, Sanjay Kaul

October 30, 2016

Presentation TCT 2016

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in A Bayesian Framework!

Presenter: Roxana Mehran, Pascal Vranckx, Scott Berry

October 30, 2016

Presentation TCT 2016

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in a Frequentist Framework!

Presenter: Roxana Mehran, Pascal Vranckx, Stuart J. Pocock

October 30, 2016

Presentation TCT 2016

How to Be a Key Investigator? Its Not Just Quantity- Quality Is Top Priority

Presenter: David A. Cox, Thomas D. Stuckey

October 30, 2016

Presentation TCT 2016

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Presenter: Roxana Mehran, Pascal Vranckx, Robert A. Harrington

October 30, 2016

Presentation TCT 2016

Quality and Compliance in Research: The Crucial First Step

Presenter: David A. Cox, Thomas D. Stuckey, Kate Dalton

October 30, 2016

Presentation TCT 2016

Vendor and Industry Relations: The Good, Bad, and Ugly

Presenter: Charles E. Chambers, Michael A. Kutcher, Ori Ben-Yehuda

October 29, 2016

Presentation TCT 2016

Can Risk-Adjusted Outcomes Differentiate Individual Operator Performance?

Presenter: Charles E. Chambers, Michael A. Kutcher, Arnold Seto

October 29, 2016

Presentation TCT 2016

SCAI AUC and PCI Risk Apps: How to Make Them Work in Your Lab

Presenter: Charles E. Chambers, Michael A. Kutcher

October 29, 2016

Presentation TCT 2016

The 10 Most Important Quality Metrics for Your Cath Lab

Presenter: Charles E. Chambers, Michael A. Kutcher

October 29, 2016

Presentation

2016 TCTMD Exercise Survey

October 26, 2016

Presentation

Effectiveness of Quality Improvement Interventions at Reducing Inappropriate Cardiac Imaging

Presenter: D. Chaudhuri

January 05, 2016

Presentation

Modest Associations Between EHR Use andAcute MI Quality of Care and Outcomes

Presenter: Jonathan R. Enriquez

October 29, 2015

Advertisement

Importance of Unmeasured Confounders in Observational Registries: ASCERT and Other Examples

Value and Hazards of Subgroup Analysis: the SYNTAX to EXCEL Case Study

Clinical Trial Interpretation: Relative vs Absolute Differences

Levels of Evidence: Single-center vs Multicenter Trials

Should Clinical Trial Interpretation Be Dominated by A P Value of 0.05 for the Primary Endpoint?

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in A Bayesian Framework!

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in a Frequentist Framework!

How to Be a Key Investigator? Its Not Just Quantity- Quality Is Top Priority

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Quality and Compliance in Research: The Crucial First Step

Vendor and Industry Relations: The Good, Bad, and Ugly

Can Risk-Adjusted Outcomes Differentiate Individual Operator Performance?

SCAI AUC and PCI Risk Apps: How to Make Them Work in Your Lab

The 10 Most Important Quality Metrics for Your Cath Lab

2016 TCTMD Exercise Survey

Effectiveness of Quality Improvement Interventions at Reducing Inappropriate Cardiac Imaging

Modest Associations Between EHR Use andAcute MI Quality of Care and Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content